Cenforce, primarily known for treating erectile dysfunction, contains sildenafil citrate, which is also effective in managing pulmonary arterial hypertension (PAH). In PAH, the blood vessels in the lungs become narrowed, increasing pressure and making the heart work harder. Sildenafil in Cenforce works by inhibiting the enzyme phosphodiesterase type 5 (PDE5), which is abundant in the lungs.
This inhibition leads to relaxation of the pulmonary blood vessels, allowing for improved blood flow and reduced pressure in the lungs. As a result, it enhances oxygen delivery, reduces strain on the heart, and improves exercise capacity and symptoms in PAH patients. While Cenforce is not the FDA-approved brand for PAH (Revatio is), it contains the same active ingredient and mechanism of action. However, any use of Cenforce for PAH should be under strict medical supervision due to potential side effects and dosage differences.
